The role of nonhuman primate models in AIDS vaccine development

Molecular Medicine Today

Volumn 6, Issue 7, 2000, Pages 267-270

  Johnston, Margaret I ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 160; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PROTEIN P27; VIRUS ENVELOPE PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL MODEL; ARTICLE; CHIMERA; CHIMPANZEE; CYTOTOXIC T LYMPHOCYTE; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MACACA; NONHUMAN; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; MACACA; PAN TROGLODYTES; PRIMATES; SIMIAE; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 0033937744     PISSN: 13574310     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-4310(00)01724-X     Document Type: Note

References (28)

1. Harouse J.M.et al. Distinct pathogenic sequelae in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs. Science. 284:1999;816-819.
2. Nathanson N.et al. The role of nonhuman primates in the development of an AIDS vaccine. AIDS. 13(Suppl. A):1999;S113-S120.
3. van der Meide P.H.et al. Enumeration of lymphokine-secreting cells as a quantitative measure for cellular immune responses in rhesus macaques. J. Med. Primatol. 24:1995;271-281.
4. Letvin N.L.et al. Cytotoxic T lymphocytes specific for the simian immunodeficiency virus. Immunol. Rev. 170:1999;127-134.
5. Li J.et al. Infection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteins. J. Acquired Immune. Defic. Syndr. Hum. Retrovirol. 5:1992;639-646.
6. Ranjbar S.et al. The construction and evaluation of SIV/HIV chimeras that express the envelope of European HIV type 1 isolates. AIDS Res. Hum. Retroviruses. 13:1997;797-800.
7. Liu Z.Q.et al. Derivation and biological characterization of a molecular clone of SHIV(KU-2) that causes AIDS, neurological disease, and renal disease in rhesus macaques. Virology. 260:1999;295-307.
8. Reimann K.A.et al. An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys. J. Virol. 70:1996;3198-3206.
9. Reimann K.A.et al. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J. Virol. 70:1996;6922-6928.
10. Lu Y.et al. Rhesus macaques that become systemically infected with pathogenic SHIV 89.6-PD after intravenous, rectal, or vaginal inoculation and fail to make an antiviral antibody response rapidly develop AIDS. J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 19:1998;6-18.
11. Luciw P.A.et al. Persistent infection of rhesus macaques with T-cell-line-tropic and macrophage-tropic clones of simian/human immunodeficiency viruses (SHIV). Proc. Natl. Acad. Sci. U. S. A. 92:1995;7490-7494.
12. Harouse J.M.et al. Mucosal transmission of pathogenic CXCR4-utilizing SHIVSF33A variants in rhesus macaques. Virology. 248:1998;95-107.
13. Berman P.W.et al. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature. 345:1990;622-625.
14. Mooij P.et al. A clinically relevant HIV-1 subunit vaccine protects rhesus macaques from in vivo passaged simian-human immunodeficiency virus infection. AIDS. 12:1998;F15-F22.
15. Stott E.J.et al. Evaluation of a candidate human immunodeficiency virus type 1 (HIV-1) vaccine in macaques: effect of vaccination with HIV-1 gp120 on subsequent challenge with heterologous simian immunodeficiency virus-HIV-1 chimeric virus. J. Gen. Virol. 79:1998;423-432.
16. Lehner T.et al. Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques. Nat. Med. 2:1996;767-775.
17. Hu S.L.et al. Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science. 255:1992;456-459.
18. Polacino P.et al. Limited breadth of the protective immunity elicited by simian immunodeficiency virus SIVmne gp160 vaccines in a combination immunization regimen. J. Virol. 73:1999;618-630.
19. Polacino P.et al. Protection of macaques against intrarectal infection by a combination immunization regimen with recombinant simian immunodeficiency virus SIVmne gp160 vaccines. J. Virol. 73:1999;3134-3146.
20. Ahmad S.et al. Reduced virus load in rhesus macaques immunized with recombinant gp160 and challenged with simian immunodeficiency virus. AIDS Res. Hum. Retroviruses. 10:1994;195-204.
21. Hu S.L.et al. Effect of immunization with a vaccinia-HIV env recombinant on HIV infection of chimpanzees. Nature. 328:1987;721-723.
22. Benson J.et al. Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure. J. Virol. 72:1998;4170-4182.
23. Hirsch V.M.et al. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J. Virol. 70:1996;3741-3752.
24. Letvin N.L.et al. Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. Proc. Natl. Acad. Sci. U. S. A. 94:1997;9378-9383.
25. Haigwood N.L.et al. Protection from pathogenic SIV challenge using multigenic DNA vaccines. Immunol. Lett. 66:1999;183-188.
26. Robinson H.L.et al. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat. Med. 5:1999;526-534.
27. Boyer J.D.et al. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination. Nat. Med. 3:1997;526-532.
28. Heeney J.L.et al. Beta-chemokines and neutralizing antibody titers correlate with sterilizing immunity generated in HIV-1 vaccinated macaques. Proc. Natl. Acad. Sci. U. S. A. 95:1998;10803-10808.